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1. Introduction 
The term Alzheimer Disease (AD) was first proposed by the famous German psychiatrist, 
Emil Kraepelin, over a century ago, in the eighth edition of his textbook of psychiatry. AD 
was, at this time, included in the differential diagnosis of presenile dementia. Kraeppelin 
chose this name to honor one of his pupils Aloïs Alzheimer who was one of the first to 
describe the pathological pattern that hallmarks the disease (1,2): miliary foci of extracellular 
structures (senile plaque) and the intracellular flame-shaped fiberlike bundles (tangles) 
observed in the brain of a fifty years old woman who presented with dementia and 
delusions he had first clinically followed (figure 1, copyright-free). 
For decades, the term AD was used for patients whose onset of dementia was before 65 
years old. In 1977, it was admitted that physiopathological changes were the same whatever 
was the age of clinical illness begining (3). The classic clinical pattern consists in early 
episodic memory loss followed by a various combination of higher function modalities 
alterations (executive, language, visuo-spatial impairment…) reflecting the spread of the 
pathology from the medio-temporal lobe to other neo-cortical areas (4,5). Thus, actual 
diagnostic criteria for AD (NINCDS-ADRDA and DSM IV) claim that the disease is probable 
if there are cognitive impairments in two or more areas of cognition, whether memory and 
one other (aphasia, apraxia, agnosia or executive dysfunctions for DSM-IV) or two from the 
following eight: memory, language, perceptual skills, attention, constructive abilities, 
orientation, problem solving and functional abilities for NINCDS-ADRDA. Assuming that 
the deficits were progressive for both, the onset between 40 and 90 years old for NINCD-
ADRDA and that disease masquerading AD were excluded. Against neuropathological gold 
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standards, the accuracy of those criteria is low: 65-96% and their specificity against other 
dementias even lower 23-88% (6,7,8). Furthermore, these criteria impose the necessity of 
presenting dementia to make a diagnosis of AD. Howhever, it is very clear today that such 
disease begins to express itself well before the presence of dementia. Thus, focal cortical 
presentation of AD escapes diagnostic by those criteria whether because memory loss remains 
isolated like in isolated progressive amnesia (IPA), amnesic mild cognitive impairment (MCI) 
or because the presenting feature that involves an other area of cognition than memory like in 
posterior cortical atrophy, semantic dementia, primary progressive aphasia, etc…  
 
 
 
The senile plaque found in the hippocampus, temporal cortex and the nucleus basalis of 
Meynert of patient suffering from AD are made of a core of A-amyloid, proteoglycans, 
ApoE, antichimotrypsin and other proteins. A-amyloid is a protein derived proteolytically 
from a larger transmembrane protein: amyloid precursor protein (APP). The cleavage of 
APP is processed either in a non amyloidogenic way in a two step manner by the action of 
an - followed by the action of -secretase and lead to the production of the non toxic P3 
peptide. The amyloidogenic way is due to the action of a -secretase in toxic A42 and less-
toxic A40. Three genes have been associated with autosomal dominant AD, the APP gene, 
the Presenilin 1 (PSEN1) gene that codes for a protease that is part of the -secretase complex 
and Presenilin2 (PSEN2) that is also part of the -secretase complex (9). 
Actually, those three genes can be screened for AD and are estimated to be responsible for 
0.5% of all AD and 13% of early onset AD.  
According to the Alzheimer Disease & Frontotemporal Dementia Mutation Database 
(http://www.molgen.ua.ac.be/ADMutations), of the EOFAD mutations identified, PSEN1 
mutations account for the majority (81%), followed by APP (14%) and with PSEN2 
mutations identified only in a handful of families (6%). An earlier age of onset is linked to 
the presence of an APOE 4 allele and is also sought in suspected genetic AD (10,11). 
The second pathological finding in AD are neurofibrillary tangles. These tangles are 
filamentous inclusions in neurons that are mostly made of an hyperphosphorylated and 
aggregated form of au. The normal au is soluble and favors vesical transport in axons by 
promoting assembly and stability of microtubules. Abnormal accumulation of the 
hyperphosphorylated and insoluble form of au is toxic and can be found in several 
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neurodegenerative disorders including AD. In AD, The number of tangles is a marker of the 
disease’s severity.  
Recently, cerebro-spinal fluid (CSF) biomarkers (12), iconographic (13,14) and metabolic 
markers (15,16,17) have been validated as supportive criteria for the diagnostic of AD and 
cases of pathogenic mutations have been described in the preseniline genes in patients 
presenting with focal cortical presentation of AD. New approaches challenge NINCDS-
ARDA and DSM IV criteria, notably the criteria proposed by Dubois et al in 2007 (18,19) that 
include brain imaging, CSF biomarkers and genetic considerations. 
In this chapter, we will present two patients with new mutations in the PSEN 1 gene for one, 
APP gene for the other and isolated cognitive loss in both cases. We will discuss the various 
presentation of focal cortical presentation of AD and try to broaden the new criteria of 
Dubois et al to fit those presentations. 
2. Cases- reports 
2.1 Isolated progressive amnesia (IPA) associated with the London mutation of the 
APP (20) 
A fifty year old, right handed salesman consulted for memory deficits, he first noticed five 
years before. The trouble began by subjective blunders in his professional activities as 
forgetting to collect information from his customers that increased and eventually cost him 
his job. His medical history was unremarkable except for a road accident 43 years before 
without loss of consciousness. Interestingly, his family history was significant for 
personality and memory disorders in his mother, grandmother and maternal aunt who 
required institutionalization in their early sixties. Neurological examination was within 
normal limits and his Minimal Mental State Examination (MMSE) score was 28/30. Blood 
analysis and electroencephalogram didn’t reveal any abnormalities. Brain MRI was normal. 
Extensive neuropsychological examination highlighted an isolated deficit in verbal learning. 
Visual analysis of his cerebral 2-fluoro-2-deoxy-D-glucose (FDG)-PET obtained at this stage 
showed slight cortical hypometabolism on temporal tips. Those findings coupled with 
positive family history and early age of onset prompted us to perform direct sequencing on 
AD genes, namely of exons 16 and 17 of APP, exons 3 to 12 of PSEN1 and exons 9 to 13 of 
microtubule associated protein Tau. The analyses lead to the discovery of the London 
mutation (Val717Ile) in the APP gene that was reported in several autosomal dominant AD 
families. The clinical evolution was remarkable for the initial striking stability of the isolated 
progressive amnesia (IPA). Such long lasting IPA is not unheard, a case of 13 years duration 
IPA was found on autopsy to have pathological AD anomalies and there are reports of 
atypical AD preceded by years of isolated amnesia. This case shows that IPA can be a 
variant of genetically proven AD. Yet this case, even with the genetic analysis would not 
have fulfilled the NINCDS-ADRDA or DSM IV criteria (20). 
2.2 Progressive non fluent aphasia and executive disturbances associated with a 
Gly266Cys mutation in PSEN1 (unpublished data) 
A 56 years old physiotherapist consulted with her daughter for gradual-onset speech 
difficulties over a year. She never presented space or time disorientation nor had important 
behavioural changes. The core complaint was trouble to find words and effortful speech 
output due to loss of proper and common nouns. She was still working but felt increasing 
psychological tension due to her communication problems. Her familial history was 
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unremarkable, her mother died of cancer without cognitive impairment at 75 and her father 
is still alive and alert at 83 years old. Neurological examination was normal. She presented 
dyscalculia and her MMSE was 28/30, losing one point for sentence rehearsal and one for 
making a mistake in “world” spelling. Complete neuropsychological examination showed a 
mixed pattern dominated by dysexecutive and loss of speech production features and 
saliently a complete lack of episodic memory deficit. The initial diagnostic hypothesis was a 
predominantly logopenic form of primary progressive aphasia (PPA). Biological work-up 
was unremarkable. Brain MRI showed a discrete cortical atrophy and FDG-Pet highlighted 
slight biparietal cortex hypometabolism. Genetic testing was undertaken and positive for a 
heterozygous mutation in PSEN1 gene never reported before. The mutation in exon 8 
implicated an amino acid substitution of Glycine to Cysteine at codon 266. The mutation 
was absent in 500 belgian controls and mutation in the codon 267 are associated with Early 
onset AD in polish and English families which make us think that the mutation is 
pathogenic in our patient. Furthermore our patient improved with treatment by memantine 
chlorhydrate. As in our previous case of IPA, this patient would not have fulfilled the actual 
criteria for AD. 
3. Other focal cortical forms of AD 
Classical AD is diagnosed in vivo thanks to criteria centred on memory loss as the first and 
predominant complaint. Patients presenting with features masquerading other forms of 
neurodegenerative diseases like PPA, fronto-temporal dementia (FTD), Cortico-Basal 
Dementia (CBD) can be overlooked. An important study by Alladi et al sought to confront 
pathological examination with focal cortical syndromes and found that AD was the 
primarily pathological diagnosis in 34% of the cases (21). Interestingly, the proportion of 
focal cortical syndromes associated to AD pathology was different according to their clinical 
presentations. One hundred percent of posterior cerebral atrophy (PCA) was found to be 
due to AD whereas 50% of CBD, 36% of PPA and 7 % of FTD were associated with AD 
pathologies.  
We will develop in the following paragraphs the clinical features of those focal cortical 
presentations. 
3.1 Behavioural variant 
The initial case reported by Aloïs Alzheimer, Auguste D. (figure 1, copyright-free), 
presented with behavioural disorders, psychosis and delusions in combination with 
dementia… and had the pathologic anomalies that now hallmark AD. Yet behavioural 
presentation are not considered in NINCDS-ADRDA and DSM IV criteria and are even an 
exclusion feature in recently proposed Dubois et al criteria. The behavioural variant of FTD 
(bv-FTD) is the most common differential diagnosis of AD presenting with behavioural 
pattern, especially in presenile dementia. bv-FTD is the most common clinical manifestation 
of FTD that represents one of the seconds causes of cortical dementia after Alzheimer’s 
disease (22). Initial symptoms in bv-FTD patients usually include progressive personality 
and social conduct changes coupled with executive functions deficits (23,24). Changes in 
personality, loss of social abilities, apathy, reduced empathy, stereotypic behaviour, 
disinhibition are in correlation with predominantly orbito-basal and dorsolateral frontal 
atrophy found on MRI (22). Many studies tried to find distinctive neuropsychological 
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patterns or CSF biomarkers that could reliably make the difference between AD and bv-
FTD. However, pathological studies continue to demonstrate an important proportion of 
mistakes. 
3.2 Progressive aphasia 
Losing words, especially proper names, may be the first complaint of patients and may thus 
bring them to consultations. Later, difficulties classically involve common nouns and 
progress to points where fluency of speech could be seriously impaired. Every sentence can 
be broken by pauses and search for wanted words. If not found, circumlocutions can be 
substituted or sentences left unfinished. Depending on which modality of aphasia is mostly 
affected, PPA is separated in progressive non-fluent aphasia (PNFA) when effortful speech 
and phonological and/or syntaxic errors is prominent, semantic dementia (SD) (26) and 
more recently by logopenic aphasia. In SD, speech fluency is preserved but there is a 
striking anomia, impaired word comprehension and deficits in non-verbal semantic 
association tasks such as sorting and grouping objects on basis of functional characteristics 
(26). In logopenic aphasia, repetition is more affected. The localization of semantic memories 
is usually lateralized. Left parietal and temporal lobes store verbal-language semantic 
memories whereas the right parietal and temporal and parietal lobes store predominantly 
visual-spatial semantic memories. These modalities seem to be electively affected in 
semantic dementia (26,27). 
3.3 Corticobasal syndromes (CBS) 
The term corticobasal dementia was coined to describe a specific nosologic form of cortical-
subcortical degenerative disorders. Patients classically present with an asymmetric apraxia 
and extrapyramidal syndromes with rigidity, bradykinesia and tremor indicating basal-
ganglionic impairment (28). This is usually combined with an “alien hand” phenomena 
suggesting cortical involvement: the patient, though able to exert normal muscle strength, 
fail to direct voluntary action, the affected limb is unable to produce purposeful action and 
attempts result in inappropriate movement. The limb may remain in an odd posture 
without the patient’s awareness; there is some kind of hemisensory neglect and visuo-
spatial impairment. Myoclonus may also be present and may acquire a sensitive stimulus 
myoclonus pattern as the disease progresses. Initially the disease begins with one limb and 
then progresses to the other side and to cranial nerves. Apraxia of gaze and eyelids opening 
are frequent. CBS are considered distinct of AD for localized thalamoparietal metabolic 
asymmetries and lack of histopathologic hallmarks on autopsies. Yet, as time passes, most 
pathological changes associated with dementia have been described: usually tangles, 
amyloid deposits and lewy bodies. In the Alladi et al study, half of CBS had pathological 
hallmarks of AD (21) and several mutations of PSEN-1 have been described with clinical 
extrapyramidal syndromes and myoclonies (29,30). 
3.4 Posterior cortical atrophy (PCA) 
Initial manifestations are characterised by progressive visual impairment. Patients even 
usually consult an ophtalmologist for reading or driving difficulties. Features of Balint’s 
syndrome can be found such as simultagnosia (patients see the tree instead of the forest), 
ocular apraxia (inability to direct gaze accurately) and optic ataxia (an object cannot be 
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reached by visual guidance). Both simultagnosia and ocular apraxia lead to obvious reading 
difficulties (31). Visuo-spatial orientation becomes defective. Patients are thus unable to park 
a car. Their arms do not find correct sleeves of the dressing gown. The route from one place 
to another cannot be described nor can been understood. PCA can be further subsided in bi-
parietal syndrome, where object recognition and reading are preserved but with marked 
apraxia, agraphia and visuo-spatial difficulties. Occipito-temporal syndrome presented with 
alexia, aperceptive agnosia and some degree of prosopagnosia. In visual variants, there is a 
primary visual failure and failure of perceptual abilities (32). The immense majority of the 
patients with PCA do have AD with lewy body disease, prion disease, and aupathies as 
major differential diagnosis (21). The patient in the seminal description of Aloïs Alzheimer, 
Auguste D, could maybe presented initially with PCA explaining partially precocity of 
delusions described. 
3.5 Others (myoclonia, cerebellar…) 
Studies of the clinical characteristics of families with mutations in PSEN-1 show wide 
phenotypic features variety. Ranging from families in which myoclonus and seizures were 
prominent to ataxia attributed to some cerebellar pathology. Interestingly, extrapyramidal 
signs were reported in some series in as much as 50% of patients with PSEN-1 mutations 
(29) and seizures in over 20 % PSEN-2 mutations (33). 
4. Recents Dubois et al criteria and our proposed amendements 
In some way, the situation of focal cortical presentation of AD can be compared to the 
diagnosis of clinically isolated syndrome in multiple sclerosis (MS). To speak of MS, 
amnestic, clinical and paraclinical examination must reveal objective anormalities that 
implicate two or more areas of the central nervous system. If the anomaly is isolated, 
waiting for another anomaly is mandatory to confirm the diagnostic. This pitfall is 
responsible for time loss and thus of psychological and physical burden for  the patient and 
in some cases, the worsening of his prognosis. Therefore, in MS, there has been considerable 
efforts to include paraclinical features in diagnostic criteria to reduce time to diagnosis. 
Since several years, Central Nervous System MRI, CSF markers and evoked potentials are 
important features to increase the suspicion of the diagnosis. The same situation happens 
with actual criteria proposed for AD diagnosis. In cases where there is only an isolated 
cortical dysfunction without memory impairment or isolated memory impairment without 
other cortical areas involvement, a diagnosis would be postponed until some new features 
are added to the pattern. Contrary to MS, where evidenced of diagnosis can be gathered 
from many clinical or paraclinical sources, actual criteria of AD fail to consider the 
knowledge that has been accumulating for years in the field of brain imaging and 
discoveries of relatively reliable CSF biomarkers. Recently, Dubois et al concerned by the 
situation proposed their new criteria (Table 1) to replace those previous (from 1984) of the 
NINCDS-ADRDA (18). The argumentation behind the new criteria is that the previous 
NINCDS-ADRDA/DSM IV-TR ones were not including recent progresses of imaging and 
biomarkers for AD. This would be responsible for a low sensibility and sensitivity that could 
be much improved with the inclusion of CSF analysis, structural MRI and neuroilmaging 
with PET features. Those additions would lead to more accurate detection of the earliest 
stages of the disease and of its full spectrum.  
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Probable AD:  
A plus one or more supportive features B,C,D or E 
A. Presence of an early and significant episodic memory impairment that includes the 
following features:  
1. Gradual and progressive change in memory function reported by patients or 
informants over more than 6 months  
2. Objective evidence of significantly impaired episodic memory on testing: this 
generally consists of recall deficit that does not improve significantly or does not 
normalise with cueing or recognition testing and after effective encoding of 
information has been previously controlled 
3. The episodic memory impairment can be isolated or associated with other 
cognitive changes at the onset of AD or as AD advances 
Supportive features 
B. Presence of medial temporal lobe atrophy  
 Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with 
qualitative ratings using visual scoring (referenced to well characterised 
population with age norms) or quantitative volumetry of regions of interest 
(referenced to well characterised population with age norms)  
C. Abnormal cerebrospinal fluid biomarker 
 Low amyloid A1–42 concentrations, increased total au concentrations, or increased 
phospho-au concentrations, or combinations of the three  
 Other well validated markers to be discovered in the future 
D. Specific pattern on functional neuroimaging with PET 
 Reduced glucose metabolism in bilateral temporal parietal regions  
 Other well validated ligands, including those that foreseeably will emerge such as 
Pittsburg compound B or FDDNP 
E. Proven AD autosomal dominant mutation within the immediate family 
Exclusion criteria 
History 
 Sudden onset  
 Early occurrence of the following symptoms: gait disturbances, seizures, 
behavioural changes 
Clinical features 
 Focal neurological features including hemiparesis, sensory loss, visual field 
deficits  
 Early extrapyramidal signs 
Other medical disorders severe enough to account for memory and related symptoms 
 Non-AD dementia  
 Major depression 
 Cerebrovascular disease 
 Toxic and metabolic abnormalities, all of which may require specific 
investigations 
 MRI FLAIR or T2 signal abnormalities in the medial temporal lobe that are 
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consistent with infectious or vascular insults 
Criteria for definite AD 
AD is considered definite if the following are present: 
 Both clinical and histopathological (brain biopsy or autopsy) evidence of the 
disease, as required by the NIA-Reagan criteria for the post-mortem diagnosis of 
AD; criteria must both be present  
 Both clinical and genetic evidence (mutation on chromosome 1, 14, or 21) of AD; 
criteria must both be present. 
 
Dubois et al remain focused on early episodic memory impairment as core diagnostic 
criteron. The degradation of memory function must have started progressively and for over 
six month. Memory complaints can come from the patient itself or a close relative as both 
situations are associeted with high risk of developping AD (34,35). When the complaint is 
reported, objective memory testing must confirm an impaired delayed recall that is not  
normalised with cuing or recognition testing. Some studies found that delayed recall was a 
reliable predictor for AD in patients with MCI. Memory impairment can be isolated or 
associated with other cognitive changes. 
The inclusion of objective paraclinic tests as supporive features is, we believe, the important 
inovation of proposions of Dubois et al. They include findings from structural MRI, 
abnormal CSF markers, specific pattern on functionnal imaging and genetic that are 
questionnably absents from the previous NINCDS-ADRDA/DSM IV-TR criteria. 
Unfortunately, their exclusion criteria are actually quite strict. We guess that for a high 
specifity of their criteria, they choose not to consider any atypical pattern, excluding patients 
presenting with predominantly behavioural changes, extrapyramidal signs, sensory loss, 
visual fields deficits. As a consequence, all the AD focal cortical presentations exposed 
before would fail to qualify for probable AD except for IPA. The 2 cases we here report and 
other studies examining post-mortem brain pathologies from patient with alleged CBS or 
focal cortical presentations clearly argue against such exclusion criteria. Yet, it is our belief 
that with slight modifications, the score proposed by Dubois et al could encompass  
“atypical-AD“. The major modification we thus propose (table 2) is to get free of the 
memory impairment dogma in AD. 
We do not question the fact that most AD begin with episodic impairment and that 
accumulation of pathologenic almyloid plaques and tangle preferentially starts from the 
medio-temporal lobe to spread towards other neo-cortical areas. Yet, a significant proportion 
of patients presents initially with alterations of other cortical skills, even if they represent a 
small part of all AD. As the prevalence of AD is high and the population is getting old, this 
small part of a high population will make many thousands of patients to fail to be diagnosed. 
Changing episodic memory impairment as core criteria to any gradual cortical impairment 
with the supportive feature listed by Dubois et al would support a diagnosis of probable AD 
in most of these cases. We also think that early occurence of gait disturbances, behavioural 
changes, sensory loss, visual field deficits and extrapyramidal signs should not be exclusion 
criterias. There is a risk to diminish our specificty to diagnosis by using those amended 
criteria, but the active searching for supportive features wether genetic, CSF biomarkers or 
iconographic will help to diagnose early many patients and perhaps help to broaden visions 
more and more many people have of the AD clinical spectrum.   
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Probable AD:  
A plus one or more supportive features B,C,D or E 
A. Presence of an early and significant episodic memory impairment that includes the 
following features:  
1. Gradual and progressive change in any cognitive function reported by patients or 
informants over more than 6 months  
2. Objective evidence of significantly impaired at least this higher function on 
testing: in case of memory, this generally consists of recall deficit that does not 
improve significantly or does not normalise with cueing or recognition testing and 
after effective encoding of information has been previously controlled 
3. The cognitive function impairment can be isolated or associated with other 
cognitive changes at the onset of AD or as AD advances 
Supportive features 
B. Presence of predominantly medial temporal lobe atrophy  
 Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with 
qualitative ratings using visual scoring (referenced to well characterised 
population with age norms) or quantitative volumetry of regions of interest 
(referenced to well characterised population with age norms)  
C. Abnormal cerebrospinal fluid biomarker 
 Low amyloid A1–42 concentrations, increased total au concentrations, or increased 
phospho-au concentrations, or combinations of the three  
 Other well validated markers to be discovered in the future 
D. Specific pattern on functional neuroimaging with PET 
 Reduced glucose metabolism in bilateral temporal parietal regions  
 Other well validated ligands, including those that foreseeably will emerge such as 
Pittsburg compound B or FDDNP 
E. Proven AD autosomal dominant mutation within the immediate family 
Exclusion criteria 
History 
 Sudden onset  
 Early occurrence of the following symptoms: gait disturbances, seizures, 
behavioural changes 
Clinical features 
 Focal neurological features including hemiparesis, sensory loss, visual field 
deficits  
  Early extrapyramidal signs 
Other medical disorders severe enough to account for the cognitive decline and related 
symptoms 
 Non-AD dementia  
 Major depression 
 Cerebrovascular disease 
 Toxic and metabolic abnormalities, all of which may require specific 
investigations 
 MRI FLAIR or T2 signal abnormalities in the medial temporal lobe that are 
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consistent with infectious or vascular insults 
Criteria for definite AD 
AD is considered definite if the following are present: 
 Both clinical and histopathological (brain biopsy or autopsy) evidence of the 
disease, as required by the NIA-Reagan criteria for the post-mortem diagnosis of 
AD; criteria must both be present  
 Both clinical and genetic evidence (mutation on chromosome 1, 14, or 21) of AD; 
criteria must both be present. 
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